Drug · CHEMBL608
PROBUCOL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PROBUCOL. Drugs and targets, record CHEMBL608. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL608
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ABCA1 | Phospholipid-transporting ATPase ABCA1 | ATP-binding cassette sub-family A member 1 inhibitor | INHIBITOR | https://conductscience.org/library/genes/19 |
Source ChEMBL
Diseases11
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 11Source Open Targets
See all 11 diseasesTrials23
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT06225752 | Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis | Phase 3 | 5,452 | probucol | Its name | ClinicalTrials.gov | |
| NCT01013532 | PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage | Phase 4 | 1,600 | probucol | Its name | ClinicalTrials.gov | |
| NCT02483169 | PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study | Phase 4 | 800 | probucol | Its name | ClinicalTrials.gov | |
| NCT01252056 | A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy | Phase 4 | 353 | probucol | Its name | ClinicalTrials.gov | |
| NCT01291641 | Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease | Phase 4 | 342 | probucol | Its name | ClinicalTrials.gov | |
| NCT02098460 | To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject | Phase 4 | 300 | probucol | Its name | ClinicalTrials.gov | |
| NCT01349010 | Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia | Phase 3 | 264 | probucol | Its name | ClinicalTrials.gov | |
| NCT00823849 | Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker | Phase 4 | 200 | probucol | Its name | ClinicalTrials.gov | |
| NCT00823875 | Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject | Phase 4 | 200 | probucol | Its name | ClinicalTrials.gov | |
| NCT00655330 | Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy | 170 | probucol | Its name | ClinicalTrials.gov |
1 to 10 of 23
See all 23 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials39
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL608
GET https://conductscience.org/api/drugs/v1/CHEMBL608/trials?page=2